ArticleSurgical endoscopy2026
Middle hepatic artery transection in laparoscopic Kasai portoenterostomy for Type III biliary atresia: a prospective cohort study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo evaluate the clinical significance of middle hepatic artery (MHA) transection during laparoscopic Kasai portoenterostomy (KPE) in children with type III biliary atresia (BA).
methodsThis prospective cohort study enrolled 116 consecutive children with type III BA who underwent laparoscopic KPE at Huai'an Maternal and Child Health Care Hospital between January 2014 and May 2024. Among them, 92 (79.3%) patients with an intraoperatively visible MHA were included in the final analysis, and divided into two groups: the MHA transection group (n=54) and the MHA preservation group (n=38). Perioperative parameters and long-term follow-up outcomes were prospectively collected and compared between the two groups.
resultsNo statistically significant differences were noted between the two groups in terms of sex distribution, age at surgery, or body weight (all P>0.05). The operation time was significantly shorter in the MHA transection group than in the MHA preservation group [(195.5±15.0) min vs. (228.7±20.5) min, P<0.001]. There were no significant differences in intraoperative blood loss, postoperative oral feeding time, and hospital stay between the two groups (all P > 0.05). In terms of hepatic function parameters, no significant between-group differences were observed in preoperative alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and direct bilirubin (DBIL) (all P > 0.05). Similarly, no significant between‑group differences were observed in ALT, AST, TBIL, or DBIL at 1‑, 2‑, and 6‑month postoperatively (all P > 0.05). Six months after surgery, cholangitis developed in 10 cases of the MHA transection group and 6 cases of the MHA preservation group (p=0.734). The 6-month jaundice clearance rate was 70.3% in the MHA transection group and 73.6% in the MHA preservation group (P=0.728), and the 2-year native liver survival rate was 66.6 and 68.4%, respectively (P=0.860), with no statistically significant differences.
conclusionThe results from our cohort demonstrated that MHA transection was relatively safe in the short term, with no instances of hepatic segment IV ischemia or necrosis detected. As it facilitated hilar dissection, this maneuver was associated with shorter operative time, lending support to the clinical applicability of MHA transection.
Indexed as
Identifiers
42778780What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.